Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series.

Morton, Celia; Lista, Annette; Jakowenko, Nicholas; Salazar, Eric; Donahue, Kevin R

Morton, Celia; Lista, Annette; Jakowenko, Nicholas; Salazar, Eric; Donahue, Kevin R.

Afiliação

Morton C; Department of Pharmacy, Houston Methodist Hospital-Texas Medical Center, Houston, TX, 77030, USA. cmorton@houstonmethodist.org.
Lista A; Department of Pharmacy, Houston Methodist Hospital-Texas Medical Center, Houston, TX, 77030, USA.
Jakowenko N; Department of Pharmacy, Houston Methodist Hospital-Texas Medical Center, Houston, TX, 77030, USA.
Salazar E; Department of Pathology and Genomic Medicine, Houston Methodist Hospital-Texas Medical Center, Houston, TX, 77030, USA.
Donahue KR; Department of Pharmacy, Houston Methodist Hospital-Texas Medical Center, Houston, TX, 77030, USA.

J Thromb Thrombolysis ; 53(1): 235-239, 2022 Jan.

Article em En | MEDLINE | ID: mdl-34236614

Assuntos

Fator Xa; Rivaroxabana; Anticoagulantes/efeitos adversos; Inibidores do Fator Xa/efeitos adversos; Humanos; Pirazóis; Piridonas; Proteínas Recombinantes; Rivaroxabana/uso terapêutico

Palavras-chave

Anti-Xa; Anticoagulants; Factor Xa inhibitors; Hemorrhage; Reversal

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator Xa / Rivaroxabana Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google